ArticleBMC cancer2026
Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA key component of colorectal cancer (CRC) treatment is the surgical resection of the tumor, accompanied by antibiotic treatment and often chemotherapy, which severely alter the gut function and its microbiome. Thus, CRC patients commonly suffer from gastrointestinal symptoms like chronic diarrhea, which can persist in some patients for several years. Synbiotics are a mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confer a health benefit on the host. Previous randomized controlled trials have shown that synbiotics reduce rates of post-operative infections and related complications, diarrhea incidence, and inflammation. However, data on the gastrointestinal quality of life are very sparse.
methodsThe proposed LEONORA trial is a randomized controlled trial with 206 CRC patients, who shall be recruited in 10 German clinics. While 103 patients in arm 1 will receive a placebo, 103 patients in arm 2 will be given a daily synbiotic treatment for 12 weeks with 50 billion colony-forming units of 12 live bacterial strains. After the wound healing phase, patients in the intervention arm will additionally receive the dietary fiber inulin from weeks 5 to 12. Every 2 weeks, the inulin dosage will be stepwise increased from 3 g to 10 g per day to slowly train the gut microbiome and avoid flatulence. The study participants in the placebo group, on the other hand, receive maltodextrin as a second placebo, which is very similar to inulin in appearance and taste, but does not affect the gut microbiome. The primary endpoint is the gastrointestinal quality of life 90 days after surgery. Further outcomes include rates of infections, cancer recurrence, cancer survival, blood-based inflammatory biomarkers, and metabolites. Stool samples will be collected to additionally address changes in the gut microbiome and metabolome composition. DISCUSSION: The 3-month therapy with synbiotics could be a well-tolerated and very cost-effective approach to increase the gastrointestinal quality of life of CRC patients. Thus, the results of the proposed LEONORA trial will be of high relevance for both caregivers and CRC patients.
trial registrationGerman Clinical Trials Register (DRKS): DRKS00034919, November 21, 2024; https://www.drks.de/search/de/trial/DRKS00034919 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.